Petros Grivas: ‘Embarrassment of riches’ in BCG-unresponsive NMIBC
Tom Powles, Professor at the University of London and Director of Barts Cancer Centre, shared a post on X:
“Updated SUNRISE1 -TAR-200 has a CR rate 83% (50% at 12 months) in BCG unresponsive NMIBC.
Impressive. Other single arm data for Il-15/ adenovival vectors are within the same range.
Cross trial comparisons of modest sized single arm trials is tricky. AUA25 time for randomisation?”
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, reshared the post on X, adding:
“Great question Tom Powles.
The data from cretostimogene trial & retrospective data with Gem/doce also look very good!
We finally have “embarrassment of riches” in BCG-unresponsive NMIBC!
Future trials need randomization but what would be the control arm?”
Tom Powles discussed new data from the SUNRISE-1 trial, noting high complete response rates for TAR-200 in BCG-unresponsive NMIBC. Petros Grivas echoed the positive outlook and emphasized the growing number of effective treatments, while pointing out the need for randomized trials.
More posts featuring Petros Grivas.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023